Kallie Belfield
Family · Potosi, MONPI 1285171462
Payments from drug & device makers
Across 218 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Lilly USA, LLC$337
- Pfizer$126
- Biohaven Pharmaceuticals, Inc.$126
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$119
- Otsuka America Pharmaceutical, Inc.$111
- plus $860 from 20 others
What the payments were for
- Food & beverage$4,196100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 131 | $2,518 |
| Lilly USA, LLC | 20 | $337 |
| Pfizer | 8 | $126 |
| Biohaven Pharmaceuticals, Inc. | 5 | $126 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $119 |
| Otsuka America Pharmaceutical, Inc. | 7 | $111 |
| Harmony Biosciences LLC | 3 | $108 |
| Braeburn Inc. | 4 | $82 |
| Boehringer Ingelheim | 1 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Vanda Pharmaceuticals Inc. | 4 | $66 |
| AstraZeneca | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| GSK | 2 | $48 |
| Alkermes, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Novo Nordisk | 2 | $36 |
| Gilead | 2 | $34 |
| Abbott | 1 | $26 |
| Amgen | 2 | $24 |
| Orexo US, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
How this compares
$4,196 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $157,135 |
| MounjaroTirzepatide | 87 | $98,212 |
| FarxigaDapagliflozin Propanediol | 83 | $55,310 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $51,046 |
| JardianceEmpagliflozin | 68 | $50,949 |
| Nurtec OdtRimegepant Sulfate | 38 | $37,526 |
| RybelsusSemaglutide | 26 | $28,813 |
| Spiriva RespimatTiotropium Bromide | 42 | $24,220 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $22,077 |
| TrulicityDulaglutide | 15 | $17,086 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $9,909 |
| Spiriva HandihalerTiotropium Bromide | 17 | $8,691 |
| LinzessLinaclotide | 14 | $7,560 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,386 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $7,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $36 | $185,948150 claims |
| Lilly USA, LLCMounjaro, Trulicity | $337 | $115,298102 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Glyxambi | $70 | $92,437142 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $60 | $81,402135 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $48 | $58,43278 claims |
| PfizerNurtec Odt, Eliquis | $126 | $43,39649 claims |
| AbbVieLinzess | $2,518 | $7,56014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Potosi
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.